Erratum: Use of nonsteroidal anti-inflammatory drugs and risk of oral cancer: A cohort study (British Journal of Cancer (2006) 95, (363-365) DOI: 10.1038/sj.bjc.6603250);Use of nonsteroidal anti-inflammatory drugs and risk of oral cancer: A cohort study

British Journal of Cancer

Volumn 95, Issue 3, 2006, Pages 363-365

  Friis, S ^a   Poulsen, A ^a   Pedersen, L ^b   Baron, J A ^c   Sorensen H T ^b  

^a INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Cohort study; Nonsteroidal anti inflammatory drugs; Oral cancer; Population based; Risk

Indexed keywords

ACETYLSALICYLIC ACID; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADOLESCENT; ADULT; ARTICLE; CANCER RISK; CHEMOPROPHYLAXIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; DENMARK; DRUG USE; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL;

EID: 33746890489     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603488     Document Type: Erratum

References (15)

1. Baron JA (2003) Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res 37: 1-24
2. Bosetti C, Talamini R, Franceschi S, Negri E, Garavello W, Vecchia CL (2003) Aspirin use and cancers of the upper aerodigestive tract. Br J Cancer 88: 672-674
3. Frank L (2000) Epidemiology. When an entire country is a cohort. Science 287: 2398-2399
4. Gaist D, Sørensen HT, Hallas J (1997) The Danish prescription registries. Dan Med Bull 44: 445-448
5. Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R (2003) Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 3: 28
6. Goodin S, Shiff SJ (2004) NSAIDs for the chemoprevention of oral cancer: promise or pessimism? Commentary re: J. L. Mulshine et al. Randomized, double-blind, placebo-controlled, phase IIB trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res 10:1565-1573, 2004. Clin Cancer Res 10: 1561-1564
7. Nelson NJ (2006) Years of research come to fruition with launch of oral cancer prevention trial. J Natl Cancer Inst 98: 88-89
8. Schneeweiss S, Glynn RJ, Tsai EH, Avorn J, Solomon DH (2005) Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology 16: 17-24
9. Skriver MV, Nørgaard M, Poulsen AH, Friis S, Harving H, Fryzek J, McLaughlin JK, Blot WJ, Olsen JH, Sørensen HT (2005) Use of nonaspirin NSAIDs and risk of lung cancer. Int J Cancer 117: 873-876
10. Sørensen HT, Friis S, Nørgard B, Mellemkjær L, Blot WJ, McLaughlin JK, Ekbom A, Baron JA (2003) Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 88: 1687-1692
11. Storm HH, Michelsen EV, Clemmensen IH, Pihl J (1997) The Danish Cancer Registry - history, content, quality and use. Dan Med Bull 44: 535-539
12. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath Jr CW (1993) Aspirin use and risk of fatal cancer. Cancer Res 53: 1322-1327
13. Ulrich CM, Bigler J, Potter JD (2006) Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 6: 130-140
14. Wang Z (2005) The role of COX-2 in oral cancer development, and chemoprevention/treatment of oral cancer by selective COX-2 inhibitors. Curr Pharm Des 11: 1771-1777
15. World Health Organization Collaborating Centre for Drug Statistics Methodology (2001) Guidelines for ATC Classification and DDD Assignments. World Health Organization Collaborating Centre for Drug Statistics Methodology: Oslo